Bulletin du cancer最新文献_第4页

[End of COBE2991®: What alternatives are available for the preparation of each type of cell therapy products? (SFGM-TC)]. [COBE2991®结束：每种类型的细胞治疗产品的制备有哪些替代品？](SFGM-TC)]。

Bulletin du cancer Pub Date : 2025-07-16 DOI: 10.1016/j.bulcan.2025.04.008

Justine Nasone, Carina Alves Goncalves, Caroline Ballot, Ulrick Birba, Maxime Bouabdelli, Lucille Capin, Alexandra Clerc, Marie Agnès Guerout Vérité, Khadija Hajjout, Antoine Haquette, Xavier Lafarge, Elisa Magrin, Florence Pierre, Eden Schwartz, Boris Calmels, Hélène Rouard, Leonardo Magro, Valérie Mialou

引用次数: 0

Epidemiological trends of hematological malignancies in North Africa: Recent insights. 北非血液恶性肿瘤的流行病学趋势：最近的见解。

Bulletin du cancer Pub Date : 2025-07-15 DOI: 10.1016/j.bulcan.2025.04.013

Salma Madihi, Hind Bouafi, Samia Boukaira, Siham Bennani, Abdelouaheb Benani

{"title":"Epidemiological trends of hematological malignancies in North Africa: Recent insights.","authors":"Salma Madihi, Hind Bouafi, Samia Boukaira, Siham Bennani, Abdelouaheb Benani","doi":"10.1016/j.bulcan.2025.04.013","DOIUrl":"https://doi.org/10.1016/j.bulcan.2025.04.013","url":null,"abstract":"Introduction: Hematologic malignancies (HMs) remain the leading cause of the global tumor burden, with growing absolute numbers. Real-world data in North Africa regarding HMs are lacking. Therefore, we aimed to report the updated insights into the prevalence, incidence, and mortality rates of HMs in North African countries to guide patient care and health policy in the region.Methods: Epidemiological data on the incidence, prevalence and mortality of HMs, including sex, age, and age-standardized rate (ASR) of HM in North African countries from 1992 to 2024 were extracted from different electronic databases.Results: Our results indicate that non-Hodgkin lymphoma (NHL) is the most prevalent HM in North Africa, exhibiting the highest incidence and mortality rates, followed by leukemia, Hodgkin lymphoma (HL) and multiple myeloma (MM), with a male predominance. Specifically, most NHL subtypes in North African countries are nodal and aggressive, including DLBCL, MALT, mantle cell lymphoma, and anaplastic B-cell lymphoma. In adolescents and children, leukemia is the first group of neoplasms reported in the region. The most frequent types are (acute leukemia) AL, including acute lymphocytic leukemia (ALL) and acute myeloid leukemia (AML), also with a male predominance. Other risk factors are linked to HMs, including bacterial and viral ones, diabetes mellitus, autoimmunity and genetic disorders.Conclusion: These findings underline the importance of region- and gender-specific research to guide healthcare policies and improve patient care.","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144651521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Are beliefs a hindrance to the process of returning to work following a diagnostic of cancer?] 在诊断出癌症后，信仰是否会阻碍人们重返工作岗位？]

Bulletin du cancer Pub Date : 2025-07-10 DOI: 10.1016/j.bulcan.2025.03.021

Julie Daul, Valérian Boudjemadi, Léa Sgambati, Odile Rohmer

{"title":"[Are beliefs a hindrance to the process of returning to work following a diagnostic of cancer?]","authors":"Julie Daul, Valérian Boudjemadi, Léa Sgambati, Odile Rohmer","doi":"10.1016/j.bulcan.2025.03.021","DOIUrl":"https://doi.org/10.1016/j.bulcan.2025.03.021","url":null,"abstract":"Introduction: Recovery from cancer is a process that encompasses all aspects of life, including returning to work. However, subjective factors such as beliefs and emotions associated with the illness can hinder this step. The aim of our study was twofold : first, to examine cancer survivors' self-beliefs and the role of self-disclosure in their psychological well-being; and second, to better understand how both beliefs and emotions influence inclusive behaviors.Methods: In Study 1, 221 cancer survivors evaluated their self-beliefs (SCM), psychological well-being (EMMBEP), and illness disclosure in the workplace. In Study 2, 158 French participants assessed their perception of cancer survivors in terms of beliefs (SCM), incorporating a fine-grained analysis of dimensions (Big Two), emotions and behaviors (BIAS Map). Data were analyzed using ANOVA and mediation models.Results: Cancer survivors perceive themselves as less competent. Moreover, while cancer survivors are generally perceived as courageous, they are judged lower in competence compared to healthy people. The perception of competence is central: it explains the relationship between the possibility of disclosing one's illness and psychological well-being (Study 1), and this perception of competence increases positive emotions and the intention to support cancer survivors (Study 2).Discussion: The perception of competence appears to be a key factor for both survivor's well-being and for the intention to support them. Finally, the possibility of self-disclosing their own illness is a factor that favors this perception of competence.","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144621583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Management of metastatic uveal melanoma: French expert consensus guidelines. 转移性葡萄膜黑色素瘤的治疗：法国专家共识指南。

Bulletin du cancer Pub Date : 2025-07-07 DOI: 10.1016/j.bulcan.2025.05.011

Manuel Rodrigues, Vincent Servois, Pascale Mariani, Marc Pracht, Caroline Dutriaux, Franck Grillet, Thomas Ryckwaert, Agnès Ducoulombier, Eve-Marie Neidhardt, Sophie Piperno-Neumann

{"title":"Management of metastatic uveal melanoma: French expert consensus guidelines.","authors":"Manuel Rodrigues, Vincent Servois, Pascale Mariani, Marc Pracht, Caroline Dutriaux, Franck Grillet, Thomas Ryckwaert, Agnès Ducoulombier, Eve-Marie Neidhardt, Sophie Piperno-Neumann","doi":"10.1016/j.bulcan.2025.05.011","DOIUrl":"https://doi.org/10.1016/j.bulcan.2025.05.011","url":null,"abstract":"Uveal melanoma (UM) is a rare malignancy originating from uveal melanocytes. Despite effective control of the primary tumour, metastatic uveal melanoma (MUM) occurs in approximately 20-30% of patients, primarily affecting the liver, with a poor prognosis and overall survival (OS). The unique molecular profile of UM, lacking BRAF, NRAS, and KIT mutations, limits targeted therapy efficacy. Chemotherapy and immune checkpoint inhibitors (ICIs) also show limited benefits, while tebentafusp has emerged as the first drug to improve OS, but this systemic treatment can be used only in HLA-A*02:01-positive patients. A French multidisciplinary panel developed evidence-based guidelines for MUM management presented in this review. Recommendations emphasise on comprehensive diagnosis, including liver biopsy and imaging, circulating tumour DNA (ctDNA) analysis, and high-definition HLA typing for HLA-A*02:01. Local therapies are proposed for patients with limited hepatic metastases, from liver surgery to isolated hepatic perfusion and chemoembolisation for patients with more extensive hepatic involvement. Systemic therapy with tebentafusp is the standard of care for HLA-A*02:01-positive patients. For HLA-A*02:01-negative patients with extensive disease, treatment options are limited. They are encouraged to participate in a clinical trial, alternatively, percutaneous hepatic perfusion, ICI alone or in combination can be proposed. Treatment efficacy assessment includes response evaluation criteria in solid tumours (RECIST), tumour growth rate (TGR) analysis, and ctDNA dynamics. This consensus provides practical guidelines for French oncologists to optimise MUM management, integrating locoregional interventions, systemic therapies, and biomarkers to enhance patient outcomes.","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144593178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development and evaluation of a new protocol for the management of immediate hypersensitivity reactions in an oncology outpatient department. 制定和评估一个新的方案，以管理肿瘤门诊部的即时过敏反应。

Bulletin du cancer Pub Date : 2025-07-07 DOI: 10.1016/j.bulcan.2025.03.020

Pierre-Yves Cren, Géraldine Rosier, Nicolas Penel, Diane Pannier, Nathalie Dereumaux, Capucine Aelbrecht-Meurisse, Geoffrey Strobbe, Diane Pelletier de Chambure

{"title":"Development and evaluation of a new protocol for the management of immediate hypersensitivity reactions in an oncology outpatient department.","authors":"Pierre-Yves Cren, Géraldine Rosier, Nicolas Penel, Diane Pannier, Nathalie Dereumaux, Capucine Aelbrecht-Meurisse, Geoffrey Strobbe, Diane Pelletier de Chambure","doi":"10.1016/j.bulcan.2025.03.020","DOIUrl":"https://doi.org/10.1016/j.bulcan.2025.03.020","url":null,"abstract":"Introduction: Management of immediate hypersensitivity reactions (HSRs) is an everyday practice issue in oncology.Objective: Our primary objective aimed to harmonize the management of HSRs. The second aim was to evaluate the implementation of this new protocol and to describe HSRs in real life settings.Methods: First, we held several multidisciplinary meetings to develop an internal consensus. Then, we conducted a prospective assessment.Results: First, this work led to a consensus, resulting in new management guidelines. Second, we identified 25 HSRs involving 23 patients (we treat about 100 patients daily, five days a week). On average, a reaction occurred every 9.8 days. According to Brown's classification, our observations included 9 grade 3 HSRs (36%), 9 grade 2 HSRs (36%), and 7 grade 1 HSRs (28%). Most frequent treatments involved in grade 3 HSRs were: Paclitaxel 3 cases (33%), Carboplatin 3 cases (33%) and Cetuximab 2 cases (22%). Following HSR, we observed a change in the planned anti-cancer treatment strategy in 76% of cases.Conclusion: Our work has standardized the management of HSRs in our cancer hospital. It also allows for close monitoring of HSRs, enabling us to understand them more clearly.","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144593177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Selection of blood products to reduce immunization before HLA-mismatched allogeneic transplantation (SFGM-TC)]. [hla -错配异体移植（SFGM-TC）前选择血液制品以减少免疫接种]。

Bulletin du cancer Pub Date : 2025-06-28 DOI: 10.1016/j.bulcan.2025.03.016

Roberto Crocchiolo, Maude Avias, Caroline Baud, Laure Croisille, Marion Francois, Nicolas Guillaume, Elham Harfouch, Thibault Pajot, Pascal Pedini, Elodie Wojciechowski, Leonardo Magro, Valérie Dubois

引用次数: 0

[Antigen vaccines in melanoma: Towards a new therapeutic paradigm]. [黑色素瘤的抗原疫苗：迈向新的治疗范式]。

Bulletin du cancer Pub Date : 2025-05-06 DOI: 10.1016/j.bulcan.2025.02.012

Clément Svabek, Sophie Maiezza, Eve Desmedt, Laurent Mortier, Marie Boileau

引用次数: 0

[Adjuvant and neoadjuvant treatments of melanoma]. [黑色素瘤的辅助和新辅助治疗]。

Bulletin du cancer Pub Date : 2025-02-28 DOI: 10.1016/j.bulcan.2024.11.014

Joséphine Cazals de Fabel, Caroline Gaudy-Marqueste

{"title":"[Adjuvant and neoadjuvant treatments of melanoma].","authors":"Joséphine Cazals de Fabel, Caroline Gaudy-Marqueste","doi":"10.1016/j.bulcan.2024.11.014","DOIUrl":"https://doi.org/10.1016/j.bulcan.2024.11.014","url":null,"abstract":"The management of melanoma has evolved significantly over the past decade with the advent of immunotherapies and BRAF/MEK inhibitors, which have changed the prognosis for patients with advanced disease. Having demonstrated their efficacy in advanced disease, these treatments have been evaluated and shown to be effective in adjuvant treatment at earlier stages, first in stage III and then in stage IIB-IIC. Alongside the development of these adjuvant treatments, which have become the standard of care, new therapeutic strategies have emerged. Neoadjuvant treatments have been shown to be superior to adjuvant treatments in phase II and III trials. These neoadjuvant strategies will undoubtedly become the new standard for patients with macroscopic lymph node disease. However, there are still many unanswered questions regarding the optimal treatment regimen. Should mono- or bi-immunotherapy be used? Can surgery be de-escalated? Is additional adjuvant treatment essential or can it be withheld in the event of a major pathological response? Should patients with BRAFV600 mutations switch to targeted therapies in the event of pathological non-response? Should we switch to targeted therapies in the event of pathological non-response in BRAFV600 mutant patients? Therapeutic strategies, which are becoming increasingly personalised, are evolving very rapidly, with a trend towards de-escalation. We still lack robust biomarkers for patient selection.","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143538241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Haematopoietic stem cell donation from minor donor: Respecting laws, assessing fitness, delivering information and good care (SFGM-TC)]. [未成年人捐献造血干细胞：尊重法律、评估健康状况、提供信息和良好护理（SFGM-TC）]。

Bulletin du cancer Pub Date : 2025-01-01 Epub Date: 2024-05-16 DOI: 10.1016/j.bulcan.2024.04.002

Marie Lejeune, Bertille Menard, Sophie Servais, Christelle Andrianne, Lucie Capelle, Ségolène De Maistre, Catherine Fabaron, Marie Flata Cornier, Marie-Pierre Goutagny, Maguy Pereira, Clea Tardy, Eric Turquet, Malek Benakli, Etienne Baudoux, Solène Evard, Catherine Faucher, Gwenaelle Herrero, Léonardo Magro, Claire Geurten

{"title":"[Haematopoietic stem cell donation from minor donor: Respecting laws, assessing fitness, delivering information and good care (SFGM-TC)].","authors":"Marie Lejeune, Bertille Menard, Sophie Servais, Christelle Andrianne, Lucie Capelle, Ségolène De Maistre, Catherine Fabaron, Marie Flata Cornier, Marie-Pierre Goutagny, Maguy Pereira, Clea Tardy, Eric Turquet, Malek Benakli, Etienne Baudoux, Solène Evard, Catherine Faucher, Gwenaelle Herrero, Léonardo Magro, Claire Geurten","doi":"10.1016/j.bulcan.2024.04.002","DOIUrl":"10.1016/j.bulcan.2024.04.002","url":null,"abstract":"Haematopoietic stem cell collection from paediatric donors is a common and life-saving practice, as evidenced by the fact that there is a growing annual number of cases of transplants from minor donors among SFGM-TC centers over the last decade. Still, medical use of human tissue from a healthy and underage donor requires proper regulations and medical management. The guidelines below aim at underlining the importance of pondering the legal, medical and ethical aspects of using stem cells from healthy paediatric donors and stress out the importance of obtaining informed consent at the time of assessing HLA compatibility. Combined medical and psychological assessments are required before the donation, as well as one month later and one year later to ensure of the child's physical and mental wellbeing. Bone marrow harvest under general anaesthetics remains the preferred method of collection for children. Peripheral blood stem cell collection should only be considered for children who will not require a central venous access for collection. We aim at offering guidelines centered on the healthy child donating stem cells and his/her wellbeing, and these should be regularly reviewed as medical practices evolve.","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":"S78-S86"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140961091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Medical simulation training for bone marrow harvesting from a healthy donor for an allogeneic hematopoietic cell transplant (SFGM-TC)]. [为异体造血细胞移植从健康捐献者身上获取骨髓的医学模拟训练（SFGM-TC）]。

Bulletin du cancer Pub Date : 2024-12-12 DOI: 10.1016/j.bulcan.2024.10.010

Tamim Alsuliman, Leonardo Magro, Marie Titecat, Marie Robin, Tarek Kanouni, Edouard Forcade, Charlotte Jubert, Ibrahim Yakoub-Agha, Catherine Faucher

引用次数: 0